A substantial percentage of Medicare beneficiaries with sleep disorders (most commonly insomnia and obstructive sleep apnea) undergo evaluations by sleep specialists.
Physiologic traits that cause obstructive sleep apnea are also associated with adherence to continuous positive airway pressure in patients with stroke.
Embolic stroke of undetermined source is associated with elevated periodic limb movements and increased sleep onset latency.
The FDA has approved Somryst™ (Pear Therapeutics), a prescription digital therapeutic (PDT) intended for the treatment of patients 22 years of age and older with chronic insomnia.
The FDA has accepted for Priority Review the New Drug Application for JZP-258 for the treatment of cataplexy or excessive daytime sleepiness in patients aged ≥7 years with narcolepsy.
Researchers examined how the associations of life event stress with impulsivity, anxiety, and depressed mood change in the presence of sleep disturbance.
Study further highlights the need to use precise and accurate depression and anxiety scales adjusted to patients not only for assessment purposes but also for the treatment of these symptoms in obstructive sleep apnea.
The presence of migraine and increasing headache pain intensity are associated with higher rates of anxiety, depression, inflammation, and sleep conditions, among other disorders.
A study of Chinese healthcare workers may foreshadow the mental health burden placed upon physicians, nurses, and other professionals as COVID-19 strains the medical system in the United States.
Conducting only a single night of portable monitoring can misclassify disease severity in patients with mild to moderate sleep apnea.
